Black Hawk Acquisition Corporation balance sheet BKHA

As of Aug 31, 2026, Black Hawk Acquisition Corporation had total assets of $26.0 million and total liabilities of $4.8 million. Total assets were up 11.5% from a year earlier. Stockholders' equity was negative, at -$4.7 million, because liabilities exceed assets. Cash and investments were $0. The current ratio, current assets divided by current liabilities, was 0.02.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Aug 31, 2026
FY 2025
Nov 30, 2025
FY 2024
Nov 30, 2024
Assets
Cash
0
0
0
Cash and investments
0
0
0
Total current assets
0
-7.1%
0
-83.8%
0
Total assets
26
+11.5%
24
-66.9%
72
Liabilities and equity
Total current liabilities
2
+146.8%
1
+1988.3%
0
Total liabilities
5
+41.3%
4
+56.8%
2
Stockholders' equity
-5
-42.0%
-4
-77.1%
-2
Ratios
Current ratio
0.02x
0.03x
4.42x
Return on assets
4.99%
5.57%
2.66%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BKHA (Nasdaq), BKHAR (Nasdaq), BKHAU (Nasdaq)
Fiscal year ends
November 30
Headquarters
Danville, CA
SEC filer status
, Emerging growth company
SEC CIK
2000775

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.